Ocular Therapeutix (OCUL) Long-Term Deferred Tax (2013)
Ocular Therapeutix (OCUL) posted quarterly Long-Term Deferred Tax of $25.8 million for Q4 2013.
Powered by 
Analysis
Ocular Therapeutix (OCUL) Long-Term Deferred Tax (2013) Analysis & Trends
Ocular Therapeutix has reported Long-Term Deferred Tax for 1 years, with the latest figure at $25.8 million in Q4 2013.
- Long-Term Deferred Tax for Q4 2013 came in at $25.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was $25.8 million (changed N/A YoY), and the FY2013 annual result was $25.8 million, changed N/A from the prior year.
- Long-Term Deferred Tax was little changed at $25.8 million in Q4 2013.
- Over five years, Long-Term Deferred Tax peaked at $25.8 million in Q4 2013 and troughed at $25.8 million in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.41 Bn | 2.41 Bn | 11.46 Mn |